U.S. approves PD-L1 monoantigen Tecentriq for first-line treatment of non-small cell lung cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SFood and Drug Administration has approved Roche's PD-L1 monoresistic Tecentriq (atezolizumab) for first-line treatment in adult patients with high PD-L1 expression without EGFR or ALK gene mutationsthe decision was based on mid-term analysis from Phase III study IMpower110, which showed that in patients with high PD-L1 expression, Tecentriq monotherapy increased total survival (OS) by 7.1 months compared to chemotherapy, with a median OS of 13.1 months and 20.2 months, respectivelyin addition, Tecentriq's security is consistent with its known security and does not raise new problemsAmong patients treated with Tecentriq, 3-4 were treated with adverse events (AE) at level 3-4, compared with 44.1% of those receiving chemotherapyTecentriq is the first and only single-drug cancer immunotherapy that can be given in three doses, allowing administration every two weeks, three weeks or four weeksin the United States, the drug has received four approvals from NSCLC, including as a single drug or in combination with targeted therapies and chemotherapy, and has been approved in combination with carais and etoposis (chemotherapy) for first-line treatment for wide-ranging small cell lung cancer in adults
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
